男性膀胱过度活动症:抗胆碱能药物之外的药物治疗与介入选择综述
该系统综述检索2000年1月至2020年10月多个数据库,纳入24项研究,评估男性膀胱过度活动症(OAB)患者抗胆碱能药物以外的治疗选择。米拉贝隆50mg证据最充分,可改善排尿频率等症状且耐受良好;BTX-A可作为三线介入治疗但自我导尿率较高;PDE-5抑制剂和神经刺激证据有限。
要点
- 米拉贝隆50mg在男性OAB中证据最充分,可减少排尿频率并耐受良好。
- 米拉贝隆50mg联合坦索罗辛可改善排尿次数、尿急发作及OAB症状评分。
- BTX-A可作为男性OAB三线介入治疗,但间歇自我导尿率5-42%。
核心结论
- 米拉贝隆在男性OAB患者中安全性和有效性数据最充分。
- BTX-A初步数据支持其作为男性OAB的介入治疗选择。
- PDE-5抑制剂和神经刺激证据有限,不足以提供推荐。
研究设计与样本
- 系统综述,检索PubMed、EMBASE、Scopus、Web of Science、Cochrane Central Register of Controlled Trials及Cochrane Central Database of Systematic Reviews。
- 检索2000年1月至2020年10月发表的文献,遵循PRISMA指南,PROSPERO注册号CRD42020201223。
- 共纳入24项研究。
主要发现
- 5项RCT的汇总分析纳入1187例患者,米拉贝隆50mg较安慰剂更显著减少排尿频率(-0.37,95%CI:-0.74至-0.01,p<0.05)。
- 3项RCT的汇总分析纳入1317例男性患者,在α1受体阻滞剂坦索罗辛基础上加用米拉贝隆50mg,改善每日平均排尿次数(-0.27,95%CI:-0.46至-0.09,p<0.05)、尿急发作(-0.50,95%CI:-0.77至-0.22,p<0.05)、OAB症状总分(-0.66,95%CI:-1.00至-0.38,p<0.05)及平均每次排尿量(+10.76ml,95%CI:4.87-16.64,p<0.05)。
- 米拉贝隆在男性中耐受良好。
- BTX-A在男性OAB中作为三线治疗似乎有效,但间歇自我导尿率(5-42%)高于女性。
- PDE-5抑制剂应视为研究性治疗,神经刺激数据稀少。
关键数值与推荐
- 米拉贝隆50mg为抗胆碱能药物治疗失败后证据等级最高的选择。
- BTX-A可作为介入治疗选项,但需注意间歇自我导尿率5-42%。
- PDE-5抑制剂和神经刺激因证据不足,无法提供推荐。
临床怎么用
- 男性OAB患者抗胆碱能药物失败后,可优先考虑米拉贝隆50mg。
- 米拉贝隆50mg可与坦索罗辛联合用于男性OAB患者。
- BTX-A可作为三线介入治疗,但需告知间歇自我导尿风险。
- PDE-5抑制剂和神经刺激暂不推荐常规使用,需进一步研究。
局限性
- 男性OAB患者抗胆碱能药物之外治疗的数据总体稀少。
- 神经刺激相关数据 scarce。
- PDE-5抑制剂证据有限,仅为研究性。
- 未来需明确最佳治疗顺序及疗效/失败预测因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: The role of overactive bladder (OAB) treatment in women beyond antimuscarinics has been evaluated extensively. Beta-3 agonists, botulinum toxin-A (BTX-A), and nerve stimulation are indicated in these patients. However, data on male patients in this clinical scenario are scarce. OBJECTIVE: The aim of this systematic review was to evaluate the evidence on treatment options beyond antimuscarinics in men with OAB. EVIDENCE ACQUISITION: A search of PubMed, EMBASE, Scopus, Web of science, Cochrane Central Register of Controlled Trials, and Cochrane Central Database of Systematic Reviews databases was performed for relevant articles published between January 2000 and October 2020, using the following Medical Subject Headings: "male/man," "LUTS," "overactive bladder," "storage symptoms," "urgency," "nocturia," "incontinence," "beta-3 agonist," "PDE-5 inhibitors," "botulinum toxin," "sacral nerve stimulation/neurostimulation," "percutaneous/transcutaneous tibial nerve stimulation," "PTENS," and "combination therapy." Evidence acquisition was performed according to Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. PROSPERO registration number is CRD42020201223. EVIDENCE SYNTHESIS: Overall, 24 studies were retrieved. In male OAB, mirabegron (MIRA) is the most intensively investigated pharmacological option. A pooled analysis of five randomized clinical trials (RCTs), including 1187 patients, concluded that MIRA 50 mg was associated with a greater reduction in frequency versus placebo (-0.37, 95% confidence interval [CI]: -0.74, -0.01, p < 0.05). A pooled analysis of three RCTs, including 1317 male patients, has also shown that the addition of MIRA 50 mg in men receiving the α1-blocker tamsulosin improved the mean number of micturitions per day (-0.27, 95% CI: -0.46 to -0.09, p < 0.05), urgency episodes (-0.50, 95% CI: -0.77 to -0.22, p < 0.05), total OAB symptom score (-0.66, 95% CI: -1.00 to -0.38, p < 0.05), and mean volume voided (+10.76 ml, 95% CI: 4.87-16.64, p < 0.05). MIRA treatment is well tolerated in men. Other pharmacological treatment options, such as phosphodiesterase-5 (PDE-5) inhibitors, should be considered investigational. BTX-A seems to be effective as third-line treatment in male OAB patients. A higher rate of intermittent self-catheterization (5-42%) is observed in male than in female patients. Data on nerve stimulation are scarce. CONCLUSIONS: MIRA has the most robust data in terms of safety and efficacy in this patient population. Preliminary data in men suggest that BTX-A is indicated as an interventional treatment. Evidence for PDE-5 inhibitors and nerve stimulation is too limited to provide recommendations. Future studies in this population should aim to better define the best treatment sequence and to identify predictors for treatment response and failure, to determine a therapeutic approach tailored to patients' characteristics. PATIENT SUMMARY: Overactive bladder is highly prevalent in men. Mirabegron 50 mg is the treatment option supported by the highest level of evidence when antimuscarinics failed. Botulinum toxin A injections seems to be an effective treatment as interventional option. Roles of nerve stimulation and phosphodiesterase inhibitors in male OAB patients are still to be defined.
引用
- De Nunzio C, Brucker B, Bschleipfer T, et al. Beyond Antimuscarinics: A Review of Pharmacological and Interventional Options for Overactive Bladder Management in Men. Eur Urol. 2021. PMID: 33402296. doi:10.1016/j.eururo.2020.12.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。